Loading clinical trials...
Loading clinical trials...
A Single-Center Prospective Cohort Study to Evaluate the Efficacy and Safety of Intensifying Treatment with Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (non-APL) and Exhibiting Lower Early Peripheral Blast Clearance Rate After Standard Intensive Induction Chemotherapy
Conditions
Interventions
Venetoclax
Idarubincin
+1 more
Locations
1
China
Affiliated hospital of Nantong University
Nantong, Jiangsu, China
Start Date
October 31, 2024
Primary Completion Date
December 31, 2025
Completion Date
October 31, 2027
Last Updated
November 12, 2024
NCT05564390
NCT00131014
NCT03050268
NCT06074666
NCT07320235
NCT06846671
Lead Sponsor
Affiliated Hospital of Nantong University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions